Archives of the Turkish Society of Cardiology
Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2014; 42(5): 482-490 | DOI: 10.5543/tkda.2014.08838

Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease

İbrahim Yıldız1, Pınar Özmen Yıldız2, Oben Döven3
1Division of Cardiology, Osmaniye State Hospital, Osmaniye, Turkey
2Division of Cardiology, Kadirli State Hospital, Osmaniye, Turkey
3Department of Cardiology, Mersin University Faculty of Medicine, Mersin, Turkey

The risks and benefits of antiplatelet treatment may be different in patients with chronic kidney disease, in whom tendency to thrombosis and bleeding hazards might be increased. Chronic kidney disease is also associated with poor response to antiplatelet therapy, and this represents a potentially important clinical problem in the setting of percutaneous coronary intervention and acute coronary syndrome. The use of new, potent P2Y12 inhibitors appears promising, although special consideration should be given to possible bleeding events. This review evaluates the benefits and harms of antiplatelet drugs in patients with chronic kidney disease.

Keywords: Antiplatelet drugs, aspirin, kidney failure, chronic; clopidogrel; prasugrel; ticagrelor.

How to cite this article
İbrahim Yıldız, Pınar Özmen Yıldız, Oben Döven. Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease. Turk Kardiyol Dern Ars. 2014; 42(5): 482-490

Corresponding Author: İbrahim Yıldız, Türkiye
© Copyright 2019 Archives of the Turkish Society of Cardiology
LookUs & Online Makale